C-type natriuretic peptide in prostate cancer

APMIS

Volumn 117, Issue 1, 2009, Pages 60-67

  Nielsen, Soeren Junge ^a   Iversen, Peter ^a   Rehfeld, Jens F ^a   Jensen, Helle Lone ^a   Goetze, Jens Peter ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

C type natriuretic peptide; Immunocytochemistry; Prostate cancer; Radioimmunoassay

Indexed keywords

NATRIURETIC PEPTIDE TYPE C; NATRIURETIC PEPTIDE TYPE C 22; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; RADIOIMMUNOASSAY;

AGED; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; RADIOIMMUNOASSAY;

EID: 58649089151     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00016.x     Document Type: Article

References (25)

1. Brasso K, Friis S, Kjaer SK, Jorgensen T, Iversen P. Prostate cancer in Denmark: a 50-year population-based study. Urology 1998 51 : 590 4.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997 47 : 5 27.
3. Gronberg H. Prostate cancer epidemiology. Lancet 2003 361 : 859 64.
4. Lilja H. Biology of prostate-specific antigen. Urology 2003 62 (5 Suppl 1) : 27 33.
5. Schiffer E. Biomarkers for prostate cancer. World J Urol 2007 25 : 557 62.
6. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 1991 177 : 927 31.
7. Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K, Takeshita A, et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 1997 96 : 2272 9.
8. Doi K, Ikeda T, Itoh H, Ueyama K, Hosoda K, Ogawa Y, et al. C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 2001 21 : 930 6.
9. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005 105 : 85 93.
10. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001 98 : 4016 21.
11. Komatsu Y, Chusho H, Tamura N, Yasoda A, Miyazawa T, Suda M, et al. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab 2002 20 : 331 6.
12. Olney RC. C-type natriuretic peptide in growth: a new paradigm. Growth Horm IGF Res 2006 16 (Suppl A) : S6 14.
13. Chrisman TD, Schulz S, Potter LR, Garbers DL. Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J Biol Chem 1993 268 : 3698 703.
14. Nielsen SJ, Rehfeld JF, Pedersen F, Kastrup J, Videbaek R, Goetze JP. Measurement of pro-C-type natriuretic peptide in plasma. Clin Chem 2005 51 : 2173 6.
15. Nielsen SJ, Gotze JP, Jensen HL, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. Regul Pept 2007 146 : 204 12.
16. Del Ry S, Maltinti M, Emdin M, Passino C, Catapano G, Giannessi D. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clin Chem Lab Med 2005 43 : 641 5.
17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 : 29 36.
18. Kim SH, Lee KS, Lee SJ, Seul KH, Kim SZ, Cho KW. C-type natriuretic peptide system in rabbit oviduct. Peptides 2001 22 : 1153 9.
19. Reis AM, Jankowski M, Mukaddam-Daher S, Tremblay J, Dam TV, Gutkowska J. Regulation of the natriuretic peptide system in rat uterus during the estrous cycle. J Endocrinol 1997 153 : 345 55.
20. Wilson MJ, Ruhland AR, Quast BJ, Reddy PK, Ewing SL, Sinha AA. Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl 2000 21 : 220 6.
21. Wilson MJ, Haller R, Li SY, Slaton JW, Sinha AA, Wasserman NF. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol 2005 174 : 1124 8.
22. Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004 36 : 408 21.
23. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008 13 : 1634 45.
24. Yaron A, Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 1993 28 : 31 81.
25. Albrecht M, Mittler A, Wilhelm B, Lundwall A, Lilja H, Aumuller G, et al. Expression and immunolocalisation of neutral endopeptidase in prostate cancer. Eur Urol 2003 44 : 415 22.